Suppr超能文献

儿童医疗补助计划中的高支出药品使用情况。

High-Expenditure Pharmaceutical Use Among Children in Medicaid.

机构信息

Department of Pediatrics and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario;

Division of Pediatric Medicine, Hospital for Sick Children, Toronto, Ontario.

出版信息

Pediatrics. 2017 Sep;140(3). doi: 10.1542/peds.2017-1095. Epub 2017 Aug 1.

Abstract

BACKGROUND AND OBJECTIVES

Medication use may be a target for quality improvement, cost containment, and research. We aimed to identify medication classes associated with the highest expenditures among pediatric Medicaid enrollees and to characterize the demographic, clinical, and health service use of children prescribed these medications.

METHODS

Retrospective, cross-sectional study of 3 271 081 Medicaid-enrolled children. Outpatient medication spending among high-expenditure medication classes, defined as the 10 most expensive among 261 mutually exclusive medication classes, was determined by using transaction prices paid to pharmacies by Medicaid agencies and managed care plans among prescriptions filled and dispensed in 2013.

RESULTS

Outpatient medications accounted for 16.6% of all Medicaid expenditures. The 10 most expensive medication classes accounted for 63.9% of all medication expenditures. Stimulants (amphetamine-type) accounted for both the highest proportion of expenditures (20.6%) and days of medication use (14.0%) among medication classes. Users of medications in the 10 highest-expenditure classes were more likely to have a chronic condition of any complexity (77.9% vs 41.6%), a mental health condition (35.7% vs 11.9%), or a complex chronic condition (9.8% vs 4.3%) than other Medicaid enrollees (all < .001). The 4 medications with the highest spending were all psychotropic medications. Polypharmacy was common across all high-expenditure classes.

CONCLUSIONS

Medicaid expenditure on pediatric medicines is concentrated among a relatively small number of medication classes most commonly used in children with chronic conditions. Interventions to improve medication safety and effectiveness and contain costs may benefit from better delineation of the appropriate prescription of these medications.

摘要

背景与目的

药物治疗可能是提高医疗质量、控制成本和开展研究的目标。我们旨在确定导致小儿医疗补助计划(Medicaid)受保人医疗支出最高的药物类别,并描述开具这些药物的儿童的人口统计学、临床和医疗服务使用情况。

方法

这是一项回顾性、横截面研究,共纳入 3 271 081 名 Medicaid 受保儿童。通过使用 Medicaid 机构向药房支付的交易价格和管理式医疗计划支付的交易价格,确定了 261 个相互排斥的药物类别中前 10 个最昂贵药物类别(高支出药物类别)的门诊药物支出,这些价格是在 2013 年开具和分发的处方中得出的。

结果

门诊药物占 Medicaid 总支出的 16.6%。前 10 个最昂贵的药物类别占所有药物支出的 63.9%。在药物类别中,兴奋剂(安非他命类)的支出比例最高(20.6%),用药天数也最长(14.0%)。在 10 个高支出药物类别的使用者中,患有任何复杂程度的慢性病(77.9%比 41.6%)、精神健康状况(35.7%比 11.9%)或复杂慢性病(9.8%比 4.3%)的可能性均高于其他 Medicaid 受保人(所有 P 值均<0.001)。支出最高的 4 种药物均为精神类药物。所有高支出药物类别中均存在多种药物联合使用的情况。

结论

在小儿药物方面,医疗补助计划的支出集中在少数几个药物类别,这些药物类别是患有慢性病的儿童最常使用的药物类别。为了提高药物安全性和有效性并控制成本,可能需要更好地明确这些药物的合理处方。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验